We showed that RAF dimer inhibitors including BGB‐283 and compound C when combined with MEKi yielded better antiproliferative activity in multiple K‐RAS‐mutated NSCLC and CRC cancer models. The gene discussed is RAF1; the disease is colorectal carcinoma.